KPMG Global Tech Innovator Finalist

by Stephen

Jun 22

Dublin, June 2022

Zoan Biomed was chosen as one of the finalists in the KPMG Global Tech Innovator series. With
70+ impressive entrants representing the very best innovations in Ireland, the 8 finalists got to
present to some of Ireland’s leading business personalities.
The Zoan Biomed innovation was lauded for its uniqueness, impact to industry and sustainability
credentials.

We are pleased to receive further support for our growth story, recognition of our platform and
the incredible opportunity it presents. 
We extend a sincere thank you to KPMG for hosting the series and the support they offer for Irish
innovation.

Latest News

Visiting Cellink

Thank you to the Cellink team for hosting us in their highly impressive facility in Gothenberg.

We are making excellent progress towards our development of 3D bioprinted tissue model containing sustainably grown coral skeletal particles.

2 months ago

Zoan and partners at TERMIS 2023

Zoan, Cellink and University of Galway collaboration on 3D printable coral-containing bioinks to present results at TERMIS, Manchester, 28-31st March 2023: Biocompatibility of 3D bioprinted tissue model prototypes containing sustainably grown coral skeletal particles for orthopedic applicationsE. Pernevik et. al. Zoan and partners at CELLINK and University of Galway will be presenting the early results from our coral bioink…

4 months ago

Our Sustainability Model

As a Med Tech company that aims to improve people’s health, we recognise the need to preserve a healthy environment. The link between human and environmental health is well established: the WHO states that one in four premature deaths is related to environmental issues caused by humans and the World Bank acknowledges that sustainable management…

6 months ago

Novel Collaboration between Zoan Biomed and University of Galway to Assess Laboratory Bone Formation

Zoan Biomed and the University of Galway to develop high throughput rapid assessment methods for biocompatibility and osteogenic potential of orthopaedic scaffold; reducing time to clinical data and developing a path to remove the need for animal testing.

8 months ago

Contact Us

To find out more about Zoan BioMed get in touch